CRMD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

8.150

Open

8.030

VWAP

7.96

Vol

858.92K

Mkt Cap

621.26M

Low

7.820

Amount

6.84M

EV/EBITDA(TTM)

3.76

Total Shares

78.44M

EV

618.54M

EV/OCF(TTM)

3.53

P/S(TTM)

2.04

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Show More

Events Timeline

(ET)

2026-04-27

08:10:00

CorMedix Announces Phase III Results from ReSPECT Trial

2026-03-06 (ET)

2026-03-06

17:20:00

CorMedix Maintains FY27 DefenCath Sales Outlook of $150M-$170M

2026-03-05 (ET)

2026-03-05

07:40:00

CorMedix Q4 Revenue $128.615M Beats Expectations

2026-02-02 (ET)

2026-02-02

08:40:00

CorMedix Approves $75 Million Share Repurchase Program

2026-01-08 (ET)

2026-01-08

16:30:00

Major Averages Mixed as Oil Prices Surge Nearly 4%

News

Newsfilter

05-05Newsfilter

CorMedix to Report Q1 2026 Financial Results on May 14

stocktwits

04-27stocktwits

Positive Trial Results for Rezzayo Antifungal Drug

NASDAQ.COM

04-27NASDAQ.COM

CorMedix Reports Positive Phase III Results for REZZAYO in Fungal Disease Prevention

Newsfilter

04-27Newsfilter

CorMedix Announces Positive Phase III Results for REZZAYO

Newsfilter

04-07Newsfilter

CorMedix to Participate in Needham Conference

NASDAQ.COM

03-06NASDAQ.COM

CorMedix Reports 2025 Financial Results and Guidance

4 Analyst Rating

Wall Street analysts forecast CRMD stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

13.00

Averages

13.67

High

15.00

Current: 0.000

Low

13.00

Averages

13.67

High

15.00

RBC Capital

Leonid Timashev

Outperform

maintain

$13 -> $14

AI Analysis

2026-04-28

Reason

RBC Capital

Leonid Timashev

Price Target

$13 -> $14

AI Analysis

2026-04-28

maintain

Outperform

Reason

RBC Capital analyst Leonid Timashev raised the firm's price target on CorMedix to $14 from $13 and keeps an Outperform rating on the shares. The company eported positive topline phase 3 for Rezzayo for the prophylaxis of fungal infections, and the firm's initial impression is that Rezzayo looks competitive to other options, likely having delivered on its promise of broad spectrum activity, favorable tolerability, and fewer discontinuations, the analyst tells investors in a research note.

Leerink

Outperform

to

Outperform

downgrade

$15 -> $13

2026-03-06

Reason

Leerink

Price Target

$15 -> $13

2026-03-06

downgrade

Outperform

to

Outperform

Reason

Leerink lowered the firm's price target on CorMedix to $13 from $15 and keeps an Outperform rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRMD

Unlock Now

Valuation Metrics

The current forward P/E ratio for CorMedix Inc (CRMD.O) is 18.38, compared to its 5-year average forward P/E of -3.06. For a more detailed relative valuation and DCF analysis to assess CorMedix Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.06

Current PE

18.38

Overvalued PE

37.66

Undervalued PE

-43.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

2.19

Current EV/EBITDA

3.87

Overvalued EV/EBITDA

8.67

Undervalued EV/EBITDA

-4.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

3909.61

Current PS

2.13

Overvalued PS

18117.60

Undervalued PS

-10298.39

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 17 candidates

Analyst Consensus: Strong Buy, Moderate BuyPe Ttm: 5 - 40Is Index Component: GSPC, RUT, DJI, NDXOne Week Predict Return: 0.0% - 100.0%News Driver: Positive

Ticker

Name

Market Cap$

Marathon Petroleum Corp

64.06B

McDonald's Corp

232.62B

Chevron Corp

378.92B

Cardinal Health Inc

50.83B

Riley Exploration Permian Inc

698.78M

CorMedix Inc

498.02M

find a stock that could rise 1000%

Intellectia · 20 candidates

Market Cap: 300.00M - 5.00BQuarter Revenue Yoy Growth: >= 40.0%Beta: HighRiskRevenue 5yr Cagr: >= 25List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

TG Therapeutics Inc

4.84B

MARA Holdings Inc

3.76B

Lucid Group Inc

3.58B

CorMedix Inc

628.74M

Real Brokerage Inc

766.72M

Procept Biorobotics Corp

1.61B

best stock under 20 dollars to invest in

Intellectia · 19 candidates

Market Cap: 500.00M - 10.00BPrice: <= $20.00Net Margin: >= 20.00Weekly Average Turnover: >= 1,000,000Pe Ttm: <= 15Annual Eps Yoy Growth: >= 40.0%

Ticker

Name

Market Cap$

Centerra Gold Inc

3.55B

Fortuna Mining Corp

3.30B

Qfin Holdings Inc

2.12B

Dynex Capital Inc

2.11B

Slide Insurance Holdings Inc

2.04B

SharpLink Gaming Inc

1.96B

List stocks with high sales growth rates.

Intellectia · 665 candidates

Quarter Revenue Yoy Growth: >= 10.0%Revenue 5yr Cagr: >= 10

Ticker

Name

Market Cap$

Vision Marine Technologies Inc

4.48M

BridgeBio Pharma Inc

15.06B

Eos Energy Enterprises Inc

5.68B

Bonk Inc

25.65M

Nuscale Power Corp

5.98B

Dominari Holdings Inc

65.65M

Whales Holding CRMD

Deep Track Capital, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is CorMedix Inc (CRMD) stock price today?

The current price of CRMD is 7.92 USD — it has increased 0

What is CorMedix Inc (CRMD)'s business?

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

What is the price predicton of CRMD Stock?

Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is13.67 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CorMedix Inc (CRMD)'s revenue for the last quarter?

CorMedix Inc revenue for the last quarter amounts to 128.62M USD, increased 312.10

What is CorMedix Inc (CRMD)'s earnings per share (EPS) for the last quarter?

CorMedix Inc. EPS for the last quarter amounts to 0.15 USD, decreased -31.82

How many employees does CorMedix Inc (CRMD). have?

CorMedix Inc (CRMD) has 191 emplpoyees as of May 11 2026.

What is CorMedix Inc (CRMD) market cap?

Today CRMD has the market capitalization of 621.26M USD.